WO2023062451 - PEGYLATED TAT-EFSEVIN-TA AS AN ANTIARRHYTHMIC AGENT WITH FAVORABLE EFFECT ON HEART FAILURE CAUSED BY ARRHYTHMIA
National phase entry is expected:
Publication Number
WO/2023/062451
Publication Date
20.04.2023
International Application No.
PCT/IB2022/058050
International Filing Date
28.08.2022
Title **
[English]
PEGYLATED TAT-EFSEVIN-TA AS AN ANTIARRHYTHMIC AGENT WITH FAVORABLE EFFECT ON HEART FAILURE CAUSED BY ARRHYTHMIA
[French]
TAT-EFSEVINE-TA PEGYLÉE EN TANT QU'AGENT ANTIARYTHMIE AYANT UN EFFET FAVORABLE SUR L'INSUFFISANCE CARDIAQUE PROVOQUÉE PAR L'ARYTHMIE
Applicants **
FARHADI ANDAR ABI, Ali
Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Meshkin Fam St
Shiraz, 7143918596, IR
ABOEIMEHRIZI, Haniyeh
Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Meshkin Fam St
Shiraz, 7143918596, IR
Inventors
MALEKZADEH, Mohammadhossein
first floor no 1 second dead end melli bank alley azadi bolivar emam square
Sari, 4815764474, IR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP India
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 879 | |
| EPO | Filing, Examination | 4913 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 482 | |
| USA | Filing, Examination | 5635 |
Total: 12498 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The combination of the three substances TAT, efsevin, and TA along with PEG results in "PEGylated TAT-Efsevin-TA" compound functions as an anti-arrhythmic agent with favorable effect on heart failure caused by arrhythmia. The production steps include three phases: in silico, in vitro, and in vivo. the pegylated TAT-Efsevin-TA compound is an anti-arrhythmic agent with targeted delivery functions in heart cells due to the presence of the TA part as a targeted drug delivery agent to the heart tissue and the TAT part as a penetrating peptide into the cells and mitochondrial membrane. the in vitro and in vivo tests the PEGylated TAT-Efsevin-TA compound exerts anti-arrhythmic activity and with favorable effect on heart failure caused by arrhythmia in a targeted manner and without any reported side effects.[French]
La combinaison des trois substances TAT, efsevine, et TA conjointement avec PEG permet d'obtenir un composé "TAT-efsevine-TA PEGylé" qui sert d'agent anti-arythmie ayant un effet favorable sur l'insuffisance cardiaque provoquée par l'arythmie. Les étapes de production comprennent trois phases : in silico, in vitro et in vivo. Le composé TAT-efsevine-TA PEGylé est un agent anti-arythmie ayant des fonctions d'administration ciblées dans des cellules cardiaques en raison de la présence de la partie TA qui sert d'agent d'administration de médicament ciblé au tissu cardiaque et de la partie TAT qui sert de peptide pénétrant dans les cellules et la membrane mitochondriale. Les essais in vitro et in vivo montrent que le composé TAT-efsevine-TA PEGylé exerce une activité anti-arythmie et a un effet favorable sur l'insuffisance cardiaque provoquée par l'arythmie d'une manière ciblée et sans effets secondaires rapportés.